Management of incidental pancreatic neuroendocrine tumor: a case report with literature review
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.This study highlights the utility of 68-Gallium PET-CT for staging and treatment planning of pancreatic neuroendocrine tumors (PNETs). Endoscopic ultrasound-guided fine-needle biopsy (EUS-FNB) is also valuable for PNET diagnosis.
Area Of Science
- Oncology
- Nuclear Medicine
- Gastroenterology
Background
- Pancreatic neuroendocrine tumors (PNETs) are rare neoplasms, constituting less than 5% of pancreatic tumors.
- Management strategies for PNETs are guided by lesion size, main pancreatic duct (MPD) caliber, and tumor malignancy features.
Observation
- A 1.2 cm pancreatic body lesion was incidentally discovered in a 71-year-old obese male during melanoma follow-up.
- Contrast-enhanced CT, MRI, and 68-Ga pancreatic scintigraphy confirmed the lesion.
- Endoscopic ultrasound (EUS) revealed a second, smaller lesion in the pancreatic tail, with a Ki-67 proliferation index below 3% after fine-needle biopsy (FNB).
Findings
- 68-Gallium PET-CT proved effective for staging the neuroendocrine neoplasm, aiding treatment planning and localization.
- EUS-FNB is indicated for suspected PNETs, though its routine diagnostic role requires further investigation.
- Surgery is recommended for PNETs exceeding 2 cm, with MPD dilation, Ki-67 > 20%, or compression symptoms.
Implications
- 68-Gallium PET-CT is a preferred imaging modality for comprehensive evaluation and management of PNETs.
- EUS-FNB plays a crucial role in the diagnostic workup of suspected pancreatic neuroendocrine tumors.
- Treatment decisions for PNETs are multifactorial, integrating imaging, biopsy results, and clinical presentation.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
